Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) has announced it will participate in the Canadian business delegation to BIOPLUS-INTERPHEX Korea (BIX) 2026, taking place October 27–30 in Seoul, South Korea. The Vancouver-based developer of Physical AI systems and Self-Driving Laboratories will be represented by Founder and CTO Professor Jason Hein and Vice President of Operations Paloma Prieto. The delegation is organised by the Trade Commissioner Service at the Embassy of Canada to Korea alongside Health Emergency Readiness Canada, with Canada designated as the Country of Honour for BIX 2026.

Key Points

  • Telescope Innovations Corp. (CSE: TELI) is a Vancouver-based developer of Physical AI systems and Self-Driving Laboratories for the pharmaceutical and high-value chemical sectors
  • The company will join the official Canadian delegation to BIX 2026 in Seoul, South Korea, from October 27–30, 2026
  • Telescope installed South Korea's first Self-Driving Lab for biopharmaceutical research at KPBMA in Seoul in December 2025
  • Investors may be watching for partnership, commercial, or investment outcomes arising from business matchmaking meetings and panel participation at the event

Telescope's Existing South Korean Foothold Ahead of BIX 2026

The announcement highlights that Telescope already has an established presence in South Korea, having installed the country's first Self-Driving Lab for biopharmaceutical research, development, and education at the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) in Seoul in December 2025. This prior deployment positions the company as a credible participant in the Korean biopharma ecosystem ahead of BIX 2026, one of Asia's leading biopharma and biomanufacturing conferences.

Planned Activities at BIX 2026 Including AI Panel and Business Matchmaking

At BIX 2026, Telescope's programme includes industry visits organised by HERC and the Trade Commissioner Service, presentations on Physical AI and Self-Driving Laboratories in pharmaceutical R&D, and one-on-one business matchmaking meetings with prospective partners, customers, and investors. The company will also join an expert panel entitled "From Algorithms to Impact: AI-Driven Decision-Making in Biopharma," examining how organisations can translate AI-generated insights into improved scientific and operational decisions.

BC-Gyeonggi Bio Connect 2026 Adds Cross-Border Collaboration Dimension

In addition to BIX activities, Telescope will participate in BC-Gyeonggi Bio Connect 2026, an event organised by the BC Korea Office that brings together British Columbia and Korean business leaders, investors, research organisations, and industry partners to explore cross-border collaboration opportunities. The release states that CTO Jason Hein expressed confidence in South Korea as a significant and growing market for biopharmaceutical innovation, noting the goal of advancing Physical AI systems and Self-Driving Labs to accelerate chemistry process development. The immediate share price impact was not clear from available public information.